136 related articles for article (PubMed ID: 7959187)
1. Impaired oesophageal transit of capsule versus tablet formulations in the elderly.
Perkins AC; Wilson CG; Blackshaw PE; Vincent RM; Dansereau RJ; Juhlin KD; Bekker PJ; Spiller RC
Gut; 1994 Oct; 35(10):1363-7. PubMed ID: 7959187
[TBL] [Abstract][Full Text] [Related]
2. Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulations.
Perkins AC; Wilson CG; Frier M; Vincent RM; Blackshaw PE; Dansereau RJ; Juhlin KD; Bekker PJ; Spiller RC
Int J Pharm; 1999 Sep; 186(2):169-75. PubMed ID: 10486435
[TBL] [Abstract][Full Text] [Related]
3. The effect of formulation on oesophageal transit.
Channer KS; Virjee JP
J Pharm Pharmacol; 1985 Feb; 37(2):126-9. PubMed ID: 2858546
[TBL] [Abstract][Full Text] [Related]
4. Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects.
Perkins AC; Blackshaw PE; Hay PD; Lawes SC; Atherton CT; Dansereau RJ; Wagner LK; Schnell DJ; Spiller RC
Clin Ther; 2008 May; 30(5):834-44. PubMed ID: 18555931
[TBL] [Abstract][Full Text] [Related]
5. Oesophageal transit of small tablets.
Robertson CS; Hardy JG
J Pharm Pharmacol; 1988 Aug; 40(8):595-6. PubMed ID: 2907022
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of esophageal transit of tablets and capsules in 30 cats.
Westfall DS; Twedt DC; Steyn PF; Oberhauser EB; VanCleave JW
J Vet Intern Med; 2001; 15(5):467-70. PubMed ID: 11596734
[TBL] [Abstract][Full Text] [Related]
7. Scintigraphic verification of adherence of a chitosan formulation to the human oesophagus.
Säkkinen M; Marvola J; Kanerva H; Lindevall K; Ahonen A; Marvola M
Eur J Pharm Biopharm; 2004 Jan; 57(1):145-7. PubMed ID: 14729090
[TBL] [Abstract][Full Text] [Related]
8. Oesophageal transit of six commonly used tablets and capsules.
Hey H; Jørgensen F; Sørensen K; Hasselbalch H; Wamberg T
Br Med J (Clin Res Ed); 1982 Dec; 285(6356):1717-9. PubMed ID: 6816343
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing the transit of a gelatin capsule in the esophagus.
Bailey RT; Bonavina L; McChesney L; Spires KJ; Muilenburg MI; McGill JE; DeMeester TR
Drug Intell Clin Pharm; 1987 Mar; 21(3):282-5. PubMed ID: 3569029
[TBL] [Abstract][Full Text] [Related]
10. Are scintigraphic esophageal transit studies necessary to detect the potential for esophageal injury of new drugs?
Weihrauch TR
Z Gastroenterol; 1995 Sep; 33(9):557-8. PubMed ID: 8525664
[No Abstract] [Full Text] [Related]
11. Oesophageal function tests: are they of value?
Channer KS; Virjee JP
Clin Radiol; 1985 Sep; 36(5):493-6. PubMed ID: 4075719
[TBL] [Abstract][Full Text] [Related]
12. Antipyrine absorption after delayed oesophageal capsule transit.
Channer KS; Roberts CJ
Br J Clin Pharmacol; 1984 Aug; 18(2):250-3. PubMed ID: 6487466
[TBL] [Abstract][Full Text] [Related]
13. A scintigraphic study of local oesophageal bolus transit: differences between patients with Barrett's oesophagus and healthy controls.
Stier AW; Stein HJ; Allescher HD; Feith M; Schwaiger M
Gut; 2002 Feb; 50(2):159-64. PubMed ID: 11788553
[TBL] [Abstract][Full Text] [Related]
14. A simple method for preparing radioactive capsules in colon transit study.
Wang SJ; Tsai SC; Lin WY; Chen GH
Eur J Nucl Med; 2000 Jul; 27(7):857-60. PubMed ID: 10952498
[TBL] [Abstract][Full Text] [Related]
15. A novel coating concept for ileo-colonic drug targeting: proof of concept in humans using scintigraphy.
Varum FJ; Hatton GB; Freire AC; Basit AW
Eur J Pharm Biopharm; 2013 Aug; 84(3):573-7. PubMed ID: 23348235
[TBL] [Abstract][Full Text] [Related]
16. Effect of bolus composition on esophageal transit: concise communication.
Fisher RS; Malmud LS; Applegate G; Rock E; Lorber SH
J Nucl Med; 1982 Oct; 23(10):878-82. PubMed ID: 7119880
[TBL] [Abstract][Full Text] [Related]
17. The effect of polyethylene glycol 400 on gastrointestinal transit: implications for the formulation of poorly-water soluble drugs.
Basit AW; Newton JM; Short MD; Waddington WA; Ell PJ; Lacey LF
Pharm Res; 2001 Aug; 18(8):1146-50. PubMed ID: 11587486
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of oesophageal transit velocity using the improved Demons technique.
De Souza MN; Xavier FE; Secaf M; Troncon LE; de Oliveira RB; Moraes ER
Nucl Med Commun; 2016 Jan; 37(1):87-91. PubMed ID: 26457596
[TBL] [Abstract][Full Text] [Related]
19. Comparative bioavailability and pharmacokinetics of investigational enteric- and film-coated formulations of flurbiprofen 100-mg tablets: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Pakistani male volunteers.
Ahmad M; Pervaiz F
Clin Ther; 2010 Mar; 32(3):607-13. PubMed ID: 20399997
[TBL] [Abstract][Full Text] [Related]
20. Investigation of human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (efavirenz).
Gao JZh; Hussain MA; Motheram R; Gray DA; Benedek IH; Fiske WD; Doll WJ; Sandefer E; Page RC; Digenis GA
J Pharm Sci; 2007 Nov; 96(11):2970-7. PubMed ID: 17542016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
